Vyera Pharmaceuticals, LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$23Kgeneral payments (2019-2025)
$41Kresearch payments (2019-2025)
1,000clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Olayemi Osiyemi | West Palm Beach, FL | Infectious Disease | $223.83 |
| Jose Menajovsky | West Palm Beach, FL | Infectious Disease | $183.68 |
| Sara Buchstein | Coral Springs, FL | Infectious Disease | $167.76 |
| Rosemary Iwunze | Fredericksburg, VA | Internal Medicine | $138.68 |
| Roberta Van Zant | Morton, IL | Family Medicine | $122.25 |
| Norman Bernstein | Fredericksburg, VA | Infectious Disease | $116.52 |
| Amy Wecker | Miami Beach, FL | Infectious Disease | $110.34 |
| Awol Ali | Fredericksburg, VA | Infectious Disease | $108.76 |
| Brian Pien | Honolulu, HI | Infectious Disease | $107.01 |
| Stephen Threlkeld | Memphis, TN | Infectious Disease | $106.72 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.